iLASIK vision correction combines AMO technologies

Article

Advanced Medical Optics (AMO) continues its commitment to the LASIK industry by reaching out to a generation of nearly 290 million people worldwide who want better everyday vision.

Advanced Medical Optics (AMO) continues its commitment to the LASIK industry by reaching out to a generation of nearly 290 million people worldwide who want better everyday vision (iLASIK vision correction).

The iLASIK procedure is a consumer-facing brand platform that communicates the advantage of two of the company's technologies: femtosecond flap creation technology (IntraLase FS) and custom laser vision correction (Advanced CustomVue). The company presented the re-branded LASIK procedure during a user group meeting at the Hilton Riverside Hotel here prior to the American Academy of Ophthalmology annual meeting.

According to Ron Bache, global vice president of marketing, AMO refractive surgery, the procedure:

•Provides one integrated platform that features advanced technology at every step.

•Can be actively marketed to all segments of "Generation i" (college students, baby boomers, and even fighter pilots).

•Establishes the company as a committed partner that is making an unmatched investment in LASIK.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.